Briacell Therapeutics CORP (BCTX) — Who Owns This Stock? 13F Breakdown (Q2 2026)

BCTX ranks #8651 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

18 institutions disclose a position in BCTX, but none treat it as a major bet — even Sabby Management, LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

UBS Group AG has added to its BCTX position for two straight quarters, increasing it by $136.9K to reach $141.4K today.

Morgan Stanley has trimmed its BCTX position for two straight quarters, cutting it by $21.5K while still holding $3.3K.

BCTX reported a net loss of $26.3M in its latest fiscal year.

• Not yet profitable — net loss of $26.3M in the latest fiscal year
• Net income declined year over year, from -$4.8M to -$26.3M
• Operating cash flow was negative, using $28.2M in cash
• Current ratio of 5.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.21x equity — within a conventional range